Exelixis Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EXELIXIS INC, and when can generic versions of EXELIXIS INC drugs launch?
EXELIXIS INC has one approved drug.
There are ten US patents protecting EXELIXIS INC drugs.
There are two hundred and five patent family members on EXELIXIS INC drugs in thirty-two countries and nineteen supplementary protection certificates in sixteen countries.
Summary for Exelixis Inc
| International Patents: | 205 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Exelixis Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 11,098,015 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | 11,091,439 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | 11,091,440 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Exelixis Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2213661 | ⤷ Try a Trial |
| Portugal | 2593090 | ⤷ Try a Trial |
| South Korea | 20200029633 | ⤷ Try a Trial |
| Spain | 2402524 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Exelixis Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2213661 | 583 | Finland | ⤷ Try a Trial | |
| 2213661 | 43/2014 | Austria | ⤷ Try a Trial | PRODUCT NAME: CABOZANTINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/890/001-003 (MITTEILUNG) 20140326 |
| 2213661 | 1490053-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/13/890 20140326 |
| 2213661 | 2014/052 | Ireland | ⤷ Try a Trial | PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
